申请人:Pfizer Inc.
公开号:US04861891A1
公开(公告)日:1989-08-29
Certain N-substituted nicotinamide compounds having formula (I) below ##STR1## and pharmaceutically acceptable acid addition salts thereof wherein R.sup.1 is 1-piperidyl, 1-(3-indolyl)ethyl, C.sub.1-4 alkyl, phenyl, 1-(1-phenylethyl), benzyl or mono-substituted benzyl wherein the substituent is methyl, methoxy, chloro or fluoro; and R.sup.2 is bicyclo[2.2.1]hept-2-yl or ##STR2## wherein Y is hydrogen, fluoro or chloro; and X is hydrogen, fluoro, chloro, methoxy, trifluoromethyl, cyano, carboxy, carbo (C.sub.1-4 alkoxy), methylcarbamoyl or dimethylcarbamoyl function as selective inhibitors of calcium-independent phosphodiesterase and are useful as antidepressants.
具有以下式(I)的某些N-取代烟酰胺化合物及其药学上可接受的酸盐,其中R.sup.1为1-哌啶基,1-(3-吲哚基)乙基,C.sub.1-4烷基,苯基,1-(1-苯乙基),苄基或单取代苄基,其中取代基为甲基,甲氧基,氯或氟;和R.sup.2为双环[2.2.1]庚-2-基或其中Y为氢,氟或氯;X为氢,氟,氯,甲氧基,三氟甲基,氰基,羧基,羧基(C.sub.1-4烷氧基),甲基氨甲酰基或二甲基氨甲酰基,作为钙非依赖性磷酸二酯酶的选择性抑制剂,并且可用作抗抑郁药。